Latest news
ImmunityBio 2Q 2026: Revenue $51.24M, EPS ($0.22) — 10-Q Summary - TradingViewTradingView · Tue, 04 Aug 2026 11:51:11 GMTDyne Therapeutics reports Q2 net loss $178.6M, cash $898.5M; BLA for z-rostudirsen accepted with PDUFA Jan 21, 2027 - TradingViewTradingView · Wed, 29 Jul 2026 20:43:04 GMTDyne Therapeutics, Inc. Q2 2026: Net loss $178.6M, EPS $(1.08) — 10-Q Summary - TradingViewTradingView · Wed, 29 Jul 2026 07:00:00 GMTWeekly Recap: Upsized offering raises ~$375M and BLA for DYNE-251 - TradingViewTradingView · Mon, 27 Jul 2026 07:00:00 GMTWeekly Recap: Dyne FDA Priority Review and Sarepta Q2 2026 results call - TradingViewTradingView · Mon, 27 Jul 2026 07:00:00 GMT